Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population

Journal of Medical Economics

Volumn 14, Issue 3, 2011, Pages 324-334

  Vekeman, Francis ^a   Lamori, Joyce C ^b   Laliberté, François ^a   Nutescu, Edith ^c   Duh, Mei Sheng ^d   Bookhart, Brahim K ^b   Schein, Jeff ^b   Dea, Katherine ^a   Olson, William H ^b   Lefebvre, Patrick ^a  

^a GROUPE D ANALYSE   (Canada)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d ANALYSIS GROUP   (United States)

Author keywords

Bleeding; Costs; Risks; Total hip replacement; Total knee replacement; Venous thromboembolism

Indexed keywords

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DATA BASE; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; METHODOLOGY; RETROSPECTIVE STUDY; RISK ASSESSMENT; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; COST OF ILLNESS; FEMALE; HEMORRHAGE; HUMANS; MALE; MANAGED CARE PROGRAMS; MEDICAL AUDIT; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM;

EID: 79956121825     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.578698     Document Type: Article

References (20)

1. Heit JA, Cohen AT, Anderson Jr FA, et al. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood 2005;106:267a. Abstract 910
2. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338-400S (Pubitemid 39302602)
3. MacDougall DA, Feliu AL, Boccuzzi SJ, et al. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 2006;63:S5-15 (Pubitemid 44672124)
4. Caprini JA, Botteman MF, Stephens JM, et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003;6:59-74 (Pubitemid 36228350)
5. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162:1245-8 (Pubitemid 34595030)
6. Ollendorf DA, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health Syst Pharm 2002;59:1750-4 (Pubitemid 35033913)
7. White RH, Gettner S, Newman JM, et al. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 2000;343:1758-64
8. White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525-31 (Pubitemid 28340985)
9. Edelsberg J, Ollendorf D, Oster G. Venous thromboembolism following major orthopedic surgery: review of epidemiology and economics. Am J Health Syst Pharm 2001;58(Suppl 2):S413
10. Costs for hospital discharges with a primary diagnosis of knee or hip replacement. Rockville, MD: U.S. Department of Health & Human Services, 2010. Available at: http://www.hcupnet.ahrq.gov. [Last accessed 29 October 2010]
11. Bullano MF, Willey V, Hauch O, et al. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 2005;11:663-73
12. Saunders ME, Grant RE. Cost effectiveness of low-molecular weight heparin versus warfarin following hip replacement surgery. J Natl Med Assoc 1998;90:677-80 (Pubitemid 128454265)
13. Colwell Jr CW, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999;81:932-40 (Pubitemid 29355002)
14. Leclerc JR, Gent M, Hirsh J, et al. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med 1998;158:873-8 (Pubitemid 28183642)
15. Oster G, Ollendorf DA, Vera-Llonch M, et al. Economic consequences of venous thromboembolism following major orthopedic surgery. Ann Pharmacother 2004;38:377-82 (Pubitemid 38235324)
16. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
17. Hitos K, Fletcher JP. Venous thromboembolism following primary total hip arthroplasty. Int Angiol 2009;28:215-21
18. Samama CM, Ravaud P, Parent F, et al. Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study. J Thromb Haemost 2007;5:2360-7 (Pubitemid 350154344)
19. Lefebvre P, Vekeman F, Nutescu EA, et al. Risk and costs of bleeding events versus risk and costs of VTE for patients undergoing total hip or total knee arthroplasty. Presented at the 30th Annual Congress of the National Association of Orthopaedic Nurses; May 15-19, 2010; Seattle, WA. Abstract 464
20. Vekeman F, Bookhart BK, Lefebvre P, et al. Incidences and associated costs for venous thromboembolism and bleeding events in patients undergoing total hip or total knee arthroplasty. Presented at the Summer Meeting of the American Society of Health System Pharmacists; June 6-9, 2010; Tampa, FL. Abstract 15-T